Cargando…
Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study
Background: Acyclovir and valacyclovir are used for the treatment and prophylaxis of infections with herpes simplex virus (HSV) and varicella zoster virus (VZV). The aim of this study is to provide insight into the pharmacodynamics (PD) of (val)acyclovir. Methods: Patients were retrospectively selec...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695373/ https://www.ncbi.nlm.nih.gov/pubmed/36365129 http://dx.doi.org/10.3390/pharmaceutics14112311 |
_version_ | 1784838043165786112 |
---|---|
author | Grit, Geeske F. Märtson, Anne-Grete Knoester, Marjolein Toren-Wielema, Marlous L. Touw, Daan J. |
author_facet | Grit, Geeske F. Märtson, Anne-Grete Knoester, Marjolein Toren-Wielema, Marlous L. Touw, Daan J. |
author_sort | Grit, Geeske F. |
collection | PubMed |
description | Background: Acyclovir and valacyclovir are used for the treatment and prophylaxis of infections with herpes simplex virus (HSV) and varicella zoster virus (VZV). The aim of this study is to provide insight into the pharmacodynamics (PD) of (val)acyclovir. Methods: Patients were retrospectively selected, based on therapeutic drug monitoring for acyclovir, to create a population pharmacokinetic (PK) model in Pmetrics. This PK model was used to develop a PK/PD model to study the effect of acyclovir levels on VZV viral load in plasma in immunocompromised patients. Results: Immunocompromised patients with known VZV viral loads in plasma were included for PK/PD modelling (N = 4, with 23 measure points); they were part of the population of 43 patients used for PK model building. The PK/PD model described the data well (r(2) = 0.83). This is a hopeful first step in clarifying the pharmacodynamics of acyclovir; however, the data in this study are limited. Conclusions: Our preliminary PK/PD model can be used in further research to determine the effect of acyclovir levels on VZV viral load. |
format | Online Article Text |
id | pubmed-9695373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96953732022-11-26 Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study Grit, Geeske F. Märtson, Anne-Grete Knoester, Marjolein Toren-Wielema, Marlous L. Touw, Daan J. Pharmaceutics Brief Report Background: Acyclovir and valacyclovir are used for the treatment and prophylaxis of infections with herpes simplex virus (HSV) and varicella zoster virus (VZV). The aim of this study is to provide insight into the pharmacodynamics (PD) of (val)acyclovir. Methods: Patients were retrospectively selected, based on therapeutic drug monitoring for acyclovir, to create a population pharmacokinetic (PK) model in Pmetrics. This PK model was used to develop a PK/PD model to study the effect of acyclovir levels on VZV viral load in plasma in immunocompromised patients. Results: Immunocompromised patients with known VZV viral loads in plasma were included for PK/PD modelling (N = 4, with 23 measure points); they were part of the population of 43 patients used for PK model building. The PK/PD model described the data well (r(2) = 0.83). This is a hopeful first step in clarifying the pharmacodynamics of acyclovir; however, the data in this study are limited. Conclusions: Our preliminary PK/PD model can be used in further research to determine the effect of acyclovir levels on VZV viral load. MDPI 2022-10-27 /pmc/articles/PMC9695373/ /pubmed/36365129 http://dx.doi.org/10.3390/pharmaceutics14112311 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Grit, Geeske F. Märtson, Anne-Grete Knoester, Marjolein Toren-Wielema, Marlous L. Touw, Daan J. Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study |
title | Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study |
title_full | Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study |
title_fullStr | Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study |
title_full_unstemmed | Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study |
title_short | Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study |
title_sort | shedding a light on acyclovir pharmacodynamics: a retrospective analysis on pharmacokinetic/pharmacodynamic modelling of acyclovir for the treatment of varicella zoster virus infection in immunocompromised patients: a pilot study |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695373/ https://www.ncbi.nlm.nih.gov/pubmed/36365129 http://dx.doi.org/10.3390/pharmaceutics14112311 |
work_keys_str_mv | AT gritgeeskef sheddingalightonacyclovirpharmacodynamicsaretrospectiveanalysisonpharmacokineticpharmacodynamicmodellingofacyclovirforthetreatmentofvaricellazostervirusinfectioninimmunocompromisedpatientsapilotstudy AT martsonannegrete sheddingalightonacyclovirpharmacodynamicsaretrospectiveanalysisonpharmacokineticpharmacodynamicmodellingofacyclovirforthetreatmentofvaricellazostervirusinfectioninimmunocompromisedpatientsapilotstudy AT knoestermarjolein sheddingalightonacyclovirpharmacodynamicsaretrospectiveanalysisonpharmacokineticpharmacodynamicmodellingofacyclovirforthetreatmentofvaricellazostervirusinfectioninimmunocompromisedpatientsapilotstudy AT torenwielemamarlousl sheddingalightonacyclovirpharmacodynamicsaretrospectiveanalysisonpharmacokineticpharmacodynamicmodellingofacyclovirforthetreatmentofvaricellazostervirusinfectioninimmunocompromisedpatientsapilotstudy AT touwdaanj sheddingalightonacyclovirpharmacodynamicsaretrospectiveanalysisonpharmacokineticpharmacodynamicmodellingofacyclovirforthetreatmentofvaricellazostervirusinfectioninimmunocompromisedpatientsapilotstudy |